Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis.

The profound impact of topical therapy on systemic biomarkers suggests that the skin compartment generates a major component of dysregulated systemic cytokines in infant AD. There may be long-term beneficial effects of correcting systemic immune dysregulation through topical therapy.